期刊
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
卷 20, 期 -, 页码 -出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/15330338211050775
关键词
nanoparticle albumin bound paclitaxel; small cell lung cancer; survival; adverse reactions
类别
资金
- Nanjing Medical Science and Technique Development Foundation [ZKX17044]
Nanoparticle albumin bound paclitaxel (Nab-P) showed good efficacy and safety as a third-line treatment for relapsed small cell lung cancer (SCLC), with an objective response rate of 24.32% and disease control rate of 81.08%. The main adverse reactions were gastrointestinal reactions, bone marrow suppression, and fatigue.
Background: Small cell lung cancer (SCLC) is a type of highly malignant tumor. It is easy to relapse and high resistant to second-line chemotherapy. There is not a standard plan for third-line and subsequent-line treatment, hence the current study aimed to explore the performance of nanoparticle albumin bound paclitaxel (Nab-P) in the third-line treatment of recurrent SCLC. Methods: A retrospective analysis of pathologically confirmed third-line SCLC patients was conducted to observe the efficacy and adverse reactions of Nab-P treatment. Results: Among the 37 SCLC patients included in the study, objective response rate was 24.32%, and disease control rate was 81.08%. The main adverse reactions were gastrointestinal reactions, bone marrow suppression, muscle and joint aches and fatigue. Adverse reactions >= level 3 included leukopenia & neutropenia (24.32%), thrombocytopenia (5.41%) and anemia (2.70%). Conclusions: As a single-agent third-line treatment for patients with relapsed SCLC, Nab-P was effective and safe.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据